treating chronic disease by targeting inflammation at its source
nodthera is developing a new class of potent and highly selective nlrp3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. we’re building a dynamic team of people across our offices in cambridge, uk; seattle, wa; and boston, ma; all united by our shared ambition, enthusiasm, and creativity.